• BioAge Labs posted a wider Q1 net loss of $22.3 million, or $0.52 per share, versus a loss of $12.9 million, or $0.36 per share, a year earlier.
• Revenue rose to $2.8 million from $1.5 million, due to increased FTE effort under the Novartis collaboration agreement.
• Research and development expense climbed to $20.4 million from $11.1 million, on higher BGE-102 costs tied to completing the Phase 1 SAD/MAD trial, preparing for planned mid-2026 proof-of-concept studies, and manufacturing.
• Cash, cash equivalents, and marketable securities totaled $384.9 million as of March 31, with runway expected through 2029; BioAge also completed an upsized follow-on offering that raised $132.3 million in gross proceeds.
• Management highlighted Phase 1 BGE-102 data showing median 86% hsCRP reductions at 60 mg and 120 mg once-daily, with Phase 2 cardiovascular-risk and Phase 1b/2a DME trials planned to start mid-2026; first IND filing for an APJ program targeted by year-end 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605080900PRIMZONEFULLFEED9716100) on May 08, 2026, and is solely responsible for the information contained therein.